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1. General Introduction 
 
Fyn is a protein belonging to the Src family of nonreceptor tyrosine kinases (SFKs), 
which also includes Src, Yes, Lck, Lyn, Hck, Fgr and Blk.  
It is a membrane protein localized in the inner layer of the cell membrane to which it 
is attached by binding with myristatic and palmitatic acids.  
Fyn plays a key role in the regulation of many signaling pathways in both normal 
cells and in those cancer.[1] This protein is involved in various biological functions 
including growth factor and cytokine receptor signaling, cell-cell adhesion, platelet 
activation, T-cell and B-cell receptor signaling, ion channel function, integrin-
mediated signaling, axon guidance, entry into mitosis and the differentiation of 
natural killer cells, oligodendrocytes, and keratinocytes.  
The overexpression of Fyn leads to the stimulation of the proliferation and of cell 
growth, to the alterations of mitogenetic signals and morphogenetic changes; all these 
phenomena underlie the development of malignancies [2]. 
 
1.1. Gene and structure of kinase Fyn 
 
Fyn is a 59 kDa protein which consists of 537 amino acids and encoded by the Fyn 
gene, located on chromosome 6q21. Nowadays, there are three know splice variants 
of Fyn that arise from alternative splicing of exon 7 of the Fyn gene [3].  
Fyn has two types of exon 7, exon 7A and exon 7B, which produce the two major 
Fyn isoform : Fyn B (exon A) and Fyn T (exon B). These two forms differ in the 
sequence of about 50 amino acids that connect the end of the SH2 domain and the 
beginning of the SH1 domain. Fyn B and Fyn T have a different tissue distribution: 
Fyn T, the ancestral isoform, is expressed mainly in the hematopoietic system,  while 
Fyn B is located in the central nervous system. 
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It is possible that this evolutionary divergence in the SH2- linker segment of Fyn T 
and Fyn B confers distinct regulatory features [4].     
Then it has been described a novel isoform, Fyn Δ7, in which exon 7 is absent [5]. 
This form has been found in blood cells, but no translated protein has been 
documented. 
Similarly to the majority of SFKs, Fyn is of a modular nature (Fig. 1); the domains of 
these proteins include a unique N-terminal sequence (SH4) , three protein modules 
including the SH3, SH2, and kinase domains (SH1) , and C-terminal tail [6]. 
 
 
 
 
 
Fig. 1: General linear protein structure of Fyn and the Src- family members. (Saito et all. 2010) 
 
 
 
 The N-terminal SH4 domain is responsible for the interaction of kinases with 
cell membranes. The anchoring of the protein to the membrane is favoured by 
the specific acylation of two amino acids residues present in the consensus 
sequence Met- Gly- Cys of the N-terminal region. After removal Met, miristate 
is attached to the N-terminal Gly-2 via amide linkage, whereas the 
palmitoylation  of Cys-3 occurs via a thioester linkage [7].  
 The unique domain is different for each member of the family SFKs. The role 
of this sequence is still to be fully cleared but also likely to be required for the 
subcellular localization of the enzyme [8]. 
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 The SH3 domain (~ 60amino acids residues) mediates intra- and inter- 
molecular protein- protein interactions necessary for the control of the 
enzymatic activity, for interaction with the substrates and for the subcellular 
localization. This domain is a β- barrel consisting of five antiparallel β- strands 
and two prominent loops called RT and n-Src loops. The interaction occurs via 
the recognition of polyproline motif (PxxP), present on the protein partner, that 
adopts a polyproline type II helical conformation that complexes with the SH3 
domain.  
 The SH2 domain (~100 amino acids residues), such as the SH3 domain, 
mediates intra- and inter- molecular protein- protein interactions. This domain 
consists of a central three- stranded β- sheet with a single helix packed against 
each side (α1 and α2). This domain forms two recognition pockets with which  
bind phosphotyrosine residues with a general pYEEI sequence : one binds the 
phosphorylated tyrosine and the other interacts with one or more hydrophobic  
residues C-terminal to the phosphotyrosine [9]. 
 The SH1 domain has the function to catalyse the transfer of a phosphate group 
from a molecule of ATP to a tyrosine residue of a substrate protein. This 
domain has a bilobal structure; the N- terminal (or small) lobe is composed by 
five β- strands and a single α-helix (also called C helix) which is an important 
component of the regulatory mechanism and the C-terminal (or large) lobe, 
containing the regulatory activation loop (A-loop), which is predominantly α- 
helical and it is the site of activating tyrosine phosphorylation.  
The large lobe contains the activation site where there is Tyr420 whose 
phosphorylation determines the complete enzyme activation. 
These two lobes form a pocket in which occur nucleotide binding (adenine 
moiety interacts with the N lobe and a short hinge segment that connects the 
two lobes) and phosphotransfer [10]. 
The central core of the catalytic domain is a region with greatest frequency of 
highly conserved residues : DFG (Asp- Phe- Gly) and APE (Ala- Pro- Glu). 
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The aspartic acid residue may interact with the phosphate groups of ATP 
through Mg
2+
 salt bridges [11], this interaction is responsible for the correct 
positioning of the phosphate to be transferred from ATP to the protein 
substrate.  
 The C- terminal region contains a critical tyrosine residue (Tyr531) involved in 
the regulation of protein activity. This residue is an inhibitory tyrosine that 
when phosphorylated binds to the SH2 domain to prevent the substrate binding 
[12].  
 
1.2. Regulation of Fyn activation 
 
The protein Fyn, as the other Src family kinases, has two regulatory tyrosine residue 
whose phosphorylation either activates (Tyr420) or inhibits (Tyr531) the activity of 
the kinase.  
The equilibrium between tyrosine phosphorylation and dephosphorylation determines 
the intramolecular interaction that regulates the activity of Fyn.  
The inactive conformation of the kinase is characterized by intramolecular 
interactions mediate by SH2 and SH3 domains. The SH2 domain binds the 
phosphorylated C-terminal tyrosine (Tyr531 residue of isoform Fyn [B] 
corresponding to the Tyr528 of the Fyn [T]) [13], while the SH3 domain binds the 
linker segment between the SH2 domain and the catalytic domain [14]. These 
structural modifications enable the SH2 domain to get closer to the large lobe and to 
the SH3 domain to approach the small lobe (Fig.2). The SH2 linker segment seems to 
serve as an adapter for the interaction of the SH3 and of catalytic domain. These 
assumed positions determine the distortions of the catalytic site such as to render it 
inactive [15]. In particular, the hydrogen bond between Glu in the αC- helix and Lys, 
required for Mg-ATP binding, is disrupted in the inactive conformation. The 
dephosphorylation of Tyr 531 causes conformational change in the kinase domain 
that leads to the formation of a hydrogen bond between Glu and Lys in the catalytic 
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domain. The enzyme is now in active form and can catalyze the intramolecular auto-
phosphorylation of Tyr420 in the activation loop. Thus the catalytic domain is in the 
active conformation allowing the access of substrates to the active site.  
 
  
 
 
Fig. 2: Structure of Src family kinases  
 
 
SFKs can also be regulated by interaction with molecules that compete with the SFKs 
domains. Interactions with these proteins destroy the inactive stabilized 
conformations of SFKs and promote the phosphorylation of these proteins by SFKs. 
Overall, full activation of SFKs seems to proceed in the following order: 
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 The substrate binds the SH2/3 domains of inactive SFKs to destabilize, and 
thus open, the closed conformation; 
 Tyrosine phosphatase dephosphorylate the Tyr531 to stabilize the active 
conformation; 
 Finally, SFKs undergo intermolecular auto-phosphorylation on Tyr 420. In this 
way, the catalytic pocket is locked into the active conformation [16]. 
Some enzymes responsible for inactivation of the kinase are: Csk (C-terminal Src 
kinase), which phosphorylates Tyr531 residue and STEP61 (striatal enriched 
phosphatase 61) which dephosphorylates Tyr420 residue[17]. In contrast, RPTPα 
(receptor protein tyrosine phosphatase-α) can activate the protein Fyn 
dephosphorylating Tyr531 residue[18].  
 
1.3. Fyn and central nervous system function  
 
Fyn performs important functions in the development and regulation of numerous 
functions of the central nervous system (CNS). This protein is found in many areas of 
the brain, including glial cells, in white matter tracts and in cultured 
oligodendrocytes. Fyn has been shown to be important for CSN myelination 
(formation of a myelin sheath around nerve fibers) and it appears to promote the 
morphological differentiation of oligodendrocytes. Evidence shows that Fyn tyrosine 
kinase is activated during the initial stages of myelination  and that it couples to 
MAG (large myelin-associated glycoprotein), F3 and NCAM120 (120kDa neural cell 
adhesion molecule). Fyn mutant mice have a deficit of myelin content in the 
forebrain [19].  
It has been demonstrated that in oligodendrocytes Fyn interacts with α-tubulin , a 
member of the tubulin family involved in the nucleation and in the polar orientation 
of microtubules, cytoskeletal structures essential for the formation of neurites. In 
addition, Fyn binds cytoskeletal protein Tau, and this interaction facilitates the 
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outgrowth of oligodendrocytes processes. Tau interacts with the Fyn SH3domain 
whereas α-tubulin binds to the  SH2 and SH3 domains [20]. 
The lack of a functional Tau-Fyn interaction may underlie of some human CSN 
degenerative diseases such as multiple sclerosis where axonal degeneration is a 
defining aspect of the clinical decline [21].  
Fyn is localized to the post-synaptic density (PSD), a receptor complex consisting of 
several receptors such as PSD95 (postsynaptic density protein 95), NMDAR (N-
methyl-D-aspartate receptor), and AMPAR (α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor). These neurotransmitter receptors and signalin 
proteins trigger neuronal excitation of the postsynaptic cells[22]. The NMDARs form 
a complex with PSD-95 through interactions between the cytoplasmic C-terminal 
tails of  their NR2 subunits and the PDZ domains of PSD-95; in this way NMDARs 
are anchored in the PSD[23].  Fyn regulates the phosphorylation and trafficking of 
NMDA through interactions with glutamate receptor subunits NR2A and NR2B, so 
Fyn induces a potentiation of synaptic NMDA- mediated [24]. Fyn is also important 
for the regulation of the formation of dendritic spines, protrusions which represent the 
single contact points between an axon and a dendrite critical for synaptic function and 
plasticity. Fyn knockout mice show an age-dependent loss of dendritic spines.  
For these reasons, Fyn seems to be involved in neurodegenerative disorders such as 
Alzheimer’s disease (AD) [25]. 
 
1.4. Fyn kinase in Alzheimer’s disease and other 
tauopathies  
 
Alzheimer’s disease is a chronic neurodegenerative disorder characterized by the 
presence of amyloid-β plaques and (Aβ) and neurofibrillary tangles. The mechanisms 
that define the disease are still unclear but it appears that a deregulation of Fyn 
protein is involved in AD pathogenesis. It was already mentioned in the previous 
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paragraph, Fyn is involved in synaptic plasticity. In addition, Fyn regulates Aβ 
production, mediates Aβ-induced synaptic deficits and neurotoxicity, and induces 
tyrosine phosphorylation of Tau [26].  
The first step, that triggers Alzheimer’s disease, seems to be the interaction between 
soluble oligomers of amyloid-β (Aβo) and cellular prion protein (PrPc). This bond is 
specific for oligomeric form, with little or no affinity for fibrillary or monomeric Aβ 
peptide. Once the Aβo- PrPc connection is formed, transformations at the level of 
neuronal biochemistry occur (Fig.3) and Fyn is activated by phosphorylation the Tyr 
420 residue.  
 
 
 
Fig. 3: mGluR5 couples amyloid-beta oligomer–cellular prion protein to post-synaptic signaling. Schematic 
illustrating a central role of Fyn in amyloid-beta oligomer (Aβo) signaling. Binding of Aβo to cellular prion 
protein (PrPC) triggers mGluR5-dependent signaling events. Proteins are clustered in the post-synaptic 
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density (PSD) and alter N-methyl-D-aspartate receptor (NMDA-R) function, calcium and protein translation. 
Tau plays a role in localizing Fyn and is a Fyn substrate. The net result of aberrant PrPC–mGluR5–Fyn 
signaling is synaptic malfunction and loss. Aβ, amyloid-beta; APP, amyloid precursor protein; PrP, prion 
protein.(Nygaard et all. Alzheimer’s Research & Therapy, 2014) 
To have the interaction between the complex Aβo- PrPc  and the Fyn protein is 
required the presence of metabotropic glutamate receptor (mGluR5), a 
transmembrane protein that links the extracellular levels of glutamate to calcium 
mobilization, to protein translation in dendrites and to tyrosine kinase signaling.  
Fyn, after being activated, performs various functions including the phosphorylation 
of NR2A and NR2B subunits of the NMDA receptor. Several in vitro studies have 
shown dendritic spine loss after an acute Aβo exposure. This destabilization of 
dendritic spines due to Aβo is not observed in Fyn-/- cultures, this shows that Fyn 
plays a key role in Aβ-induced sinaptotoxicity . 
In addition, Fyn is also involved in Tau phosphorylation. It is well known that, in 
addition to Aβ plaques, another distinctive feature of Alzheimer’s disease is the 
presence of deposits of neurofibrillary tangles containing the hiperphosphorylated 
Tau protein[27]. Of the five tyrosine residues present in the protein Tau, only Tyr 18 
is phosphorylated by Fyn. This residue, in fact, is located in the amino acid sequence 
GTYG which shows high homology with the canonical substrate sequence 
determined for Fyn (ETYG). Tau interacts with the SH3 domain of Fyn through a 
PXXP motif (pro233- pro236) [28].  
In Alzheimer’s disease it has been observed a possible interaction and synergistic 
effects between Tau protein and amyloid-β. Tau has a function to target Fyn to the 
dendritic compartment, in this way Fyn phosphorylates NMDA receptors and 
mediates the interaction with PSD95, an interaction required for amyloid-β toxicity 
[29]. 
Fyn is also able to phosphorylate α-sinuclein, a presynaptic protein implicated in 
various neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Mutation 
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analysis revealed that the phosphorylation takes place specifically on Tyr125 [30]; 
this phosphorylation is blocked by the inhibitor PP2. 
 
1.5. Fyn in cancer 
As previously reported, the protein Fyn is involved in numerous cellular functions 
including growth and cell proliferation, morphogenesis and cell motility; anomaly 
affecting these processes are the basis of the development of tumours. It has been 
observed that an overexpression of Fyn determines the morphological changes in 
normal cells that support the development and progression of cancer [3].  
It has been shown that Fyn is an important protein in the PIKE-A/ AMPK pathway. 
In addition to the well-characterized functions as a regulator of the metabolic balance, 
AMPK is also involved in cell proliferation, cell growth, cell survival and autophagy. 
PIKE-A interacts directly with AMPK and blocks its tumour suppressive function; 
this interaction is mediated by tyrosine kinase Fyn. Fyn phosphorylates PIKE-A on 
Tyr682 and Tyr774, increasing, in this way, the binding affinity by PIKE-A for 
AMPK [31].  
In addition, this phosphorylation mediated by Fyn protein has a further antiapoptotic 
effect, going to inhibit the apoptotic degradation of PIKE-A . Point mutation of 
aspartate into alanine has highlighted that D474 and D592 are the main points of 
apoptotic degradation. The fact that Y682F and Y774F mutants enhance the apoptotic 
cleavage, while the degradation is relieved in vivo after stimulating with EGF, 
suggests that the phosphorylation of PIKE-A prevents its caspases induced cleavage 
under apoptotic condition and promotes cell survival. Fyn and PIKE-A form a 
complex through the bind between the Arf- GAP domain on PIKE-A and the SH1 
domain of Fyn [32,33].  
The PI3K/Akt/PKB is often implicated in the growth of the  cancer cell and it has 
been demonstrated that Fyn and other SFKs play an important role in the regulation 
of Akt activity, through phosphorylation of tyrosine residues. In several cell lines it 
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was observed that EGF- induced tyrosine phosphorylation and kinase activity of Akt 
are both blocked by PP2, a Src family tyrosine kinase inhibitor. Then, two tyrosine 
residues were identified, Tyr 315 and Tyr 326, which are phosphorylated by Fyn and 
other SFKs, and whose replacement with two residues of phenylalanine  causes a 
decrease in the kinase activity of Akt in response to growth factors. 
These data suggest that Src family kinases directly regulate Akt activity[34].    
SFKs also seem to be involved in cell migration, the process at the base of metastatic 
disease. Metastasis are determined by the ability of cells to migrate and interact with 
its local microenvironment. Important molecules involved in the control of cell 
adhesion and cell migration are the integrins, cell surface receptors that link 
extracellular matrix (ECM) with cytoskeletal proteins. FAK (focal adhesion kinase) is 
a tyrosine kinase which transmits the adhesion signal coming from integrins to the 
intracellular signalling cascade . FAK binds the β-subunit of integrin inducing, in this 
way, its autophosphorylation  at Tyr597 and creating a binding site for SFKs. This 
complex (SFK- FAK) is further activated by phosphorylation at other sites, 
maximizing tyrosine kinase activity of FAK [35]. 
In addition, the Fyn protein interacts with PXL (paxillin), an important regulator of 
cell shape. It was observed that the overexpression of Fyn in human pancreatic cancer 
is accompanied by an up-regulation of FAK and PXL, two elements crucial to 
motility, and thus to invasion. These are cellular processes necessary for metastatic 
competence and the acquisition of the metastatic phenotype [36]. 
Another pathway through Fyn regulates cell shape and motility is its interaction with 
the Rho family of GTPases. Rho family GTPases is a subfamily of the Ras 
superfamily that is involved in regulating the intracellular actin dynamics and it 
includes Rac1, RhoA and Cdc42 [3]. In fibroblast, Cdc42 and Rac1 activation is 
associated with lamellipodia and filopodia, respectively, whereas activation of RhoA 
induces stress fiber formation. It is likely that Rac, RhoA and Cdc42 are involved in 
the control of morphological differentiation of some cells such as oligodendrocytes 
[37].  
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In addition to activating FAK, some integrins like α5β1, α1β1, α6β4, and αvβ3, are 
able to interact and activate the Src- family kinase Fyn, that in turn activates the 
adaptor protein Shc. For this interaction, caveoli-1 works as a membrane adaptor that 
facilities the coupling of the α subunit of integrin to the Fyn protein. Fyn then 
phosphorylates Shc at Tyr317, forming an activated complex that combines with 
GRB2-SOS, causing activation of the Ras- ERK cascade [38]. Ras stimulates a 
kinase cascade that culminates in the activation of the mitogen- activated protein 
kinase (MAPK) ERK. The activation of this pathway results in the progression 
through the G1 step of the cell cycle in response to mitogens.   
The integrin/ SFK-Shc/ Ras- ERK pathway (Fig. 4) connects cell adhesion with the 
progression of the cell cycle in a process called anchorage- dependent cell growth. 
Normal cells need to adhere to serum-derived extracellular matrix components for 
cell growth in vitro, on the contrary, the growth of tumour cells occurs also without 
adhering to the extracellular matrix. The overexpression of Fyn found in cancer cells 
can, thus, lead to deregulation of anchorage- dependent cell growth [39].   
 
 
 
Fig. 4: Model of integrin- mediated recruitment of Shc and activation of Ras ( Wary et all. Cell, 1998) 
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Fyn has been shown to be involved in the regulation of the rigidity of extracellular 
matrix surface. The matrix rigidity is important both for cell motility and that 
pathological events such as tumour formation and metastasis. One of the molecules 
involved in matrix force transduction is receptor- like protein tyrosine phosphatase-α 
(RPTP-α). RPTP-α  forms a complex with αvβ3 integrin and actives Fyn by 
dephosphorylation of a negative regulatory phosphotyrosine presents in C-terminal 
domain. The palmitoylation site is very important for the activation of Fyn. As the 
Fyn is both myristoylated and palmitoylated, it has a high affinity for the cell 
membrane, on the contrary, the other Src, being only myristoylated, have a low 
affinity for the membrane and are not recruited by RPTP-α . 
In addition, the level of Fyn activation is thought to be force- dependent in which 
greater forces result in greater reinforcement of integrin- cytoskeleton linkages. 
Cas, the main substrate that is phosphorylated by Fyn, is required for the rigidity 
response and is localized to the leading edge in close proximity to Fyn [40].  
It seems that cancer cells spread aggressively because the overexpression of Fyn 
leads to an exaggerated response to the rigidity of the extracellular matrix . 
Fyn facilities the formation of metastases and cell migration, promoting the 
Epithelial-mesenchymal transition (EMT). EMT is a process characterized by loss of 
cell adhesion, a switch from E-cadherin to N-cadherin and an increase in cell 
motility, in which there is a transformation of the epithelial cell phenotype in a 
mesenchymal phenotype.  
It has been observed that β6- integrin is expressed during the mesenchymal transition 
conferring the motile phenotype on SCC (squamous cell carcinoma) cells. β6-integrin 
interacts and actives Fyn, this coupling is required for the progression through EMT. 
The presence of E-cadherin is the characterizing element of the epithelial phenotype 
and there is a direct link between the downregulation of E- cadherin with the increase 
of N-cadherin. Furthermore it seems to be a direct link between N-cadherin and Fyn 
activation [41].  
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The formation of the complex β6-integrin-Fyn seems to upregulate the expression of 
the MMP-3 (matrix metalloproteinase 3) gene. This event promotes oral SCC cell 
proliferation and metastasis in vivo [42]. 
These findings suggest that Fyn has a role as mediator of metastatic disease and of 
local tumour growth. 
 
1.6.  Fyn kinase inhibitors 
 
Being involved in numerous pathway that underlie the development of various 
diseases, the protein Fyn became a very interesting pharmaceutical target for 
neurodegenerative pathologies and tumours. 
Although the Fyn can theoretically be inhibited by molecules able to interact with 
some of the various domains present in its structure, most of the inhibitors present in 
the literature bind to the enzyme’s catalytic site, by competing with the endogenous 
substrate (ATP).  
Among the data available in the literature, only one X-ray structure of Fyn 
complexed with an inhibitor (staurosporine) has so far reported ( 2DQ7 PDB code). 
 
 
Fig. 5:Structure of staurosporine. 
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Staurosporine is a no selective inhibitor (Fig. 5) that binds to the ATP binding site, by 
three hydrogen bonds, a CH-O interaction, and some hydrophobic interactions (Fig. 
6). The binding site is located in the pocket placed between the N- and C- lobes of the 
SH1 domain. The NH and keto oxygen of the amide function of the lactam ring of the 
staurosporine form two hydrogen bonds, respectivally, with the backbone carbonyl 
oxygen of Glu 342 and the backbone NH of Met344. These residues define the 
“hinge region” that is responsible for binding of the adenine ring of ATP to the 
catalytic site. Finally, the methylamino nitrogen of the glycosidic ring formed a 
hydrogen bond with Ser348. Staurosporine has a nanomolar inhibitory activity 
against Fyn (IC50 of 4.8 nM) [6]. 
 
 
Fig. 6: Stereo-diagram of the significant residues for staurosporine binding. Three hydrogen bonds and a 
CH–O interaction are shown by green and yellow lines, respectively (Kinoshita et all. Biochemical and 
Biophysical Research Communications, 2006). 
Agents targeted specifically against Fyn have not been developed clinically yet. 
Among tyrosine kinase inhibitors, some also show an inhibitory activity against Fyn. 
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1.6.1. PP1and PP2 
These two compounds, belonging to the class of pyrazolo [3,4-d] pyrimidine (Fig. 7),  
were the first inhibitors to show a combination of power and selectivity for members 
of the Src family. They are ATP-competitive inhibitors that bind to the catalytic site 
of kinase, where the pyrazole- pyrimidine system takes the place the ATP adenine. 
PP1 and PP2 have a nanomolar inhibitory activity with IC50 of 6 and 5 nM, 
respectively [43]. 
 
  Fig. 7: Structures of compounds PP1 (a) and PP2 (b). 
 
1.6.2. Compound 6f 
This molecule (Fig. 8) belongs to a series of PP1 and PP2 analogues and it shows a 
good inhibitory activity against Fyn, with an IC50 of 40 nM (whereas in the same 
conditions in which the assay were made, the IC50 of PP1 is of 50 nM) [44]. 
 
Fig. 8: Structure of compound 6f. 
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1.6.3. AP23546 
This derived purine (Fig. 9) shows excellent potency for inhibition of Src family 
kinase with an IC50 against protein Fyn of 0.2 nM. This inhibitor exhibits in vivo 
toxicity that renders it unsuitable, however, its potency and selectivity make it ideal 
to examine tumorigenic functions mediated by SFKs [45]. 
 
Fig. 9: Structure of AP23846. 
 
1.6.4. BMS-279700 
This compound, synthesized by Chen et all., is an anilinoimidazo[1,5-a]pyrido[3,2-
e]pyrazine analogue (Fig. 10), which has shown to be active against SFKs. BMS-
279700 has a nanomolar inhibitory activity against Lck, Src, Lyn and Fyn, with an 
IC50 towards the latter of 5 nM [46].  
 
Fig. 10: Structure of BMS-279700. 
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1.6.5. CT5102, CT5263, CT5264, CT5269 and CT5276 
These molecules (Fig.11), belonging to a novel series of Src kinase inhibitors, are 
more potent and selective for Src kinase enzymes than previous inhibitor, such as 
PP1. The five compounds examined exhibit excellent inhibitory activity against Fyn, 
with an IC50 ranging from 8 nM (CT5102) to 24 nM (CT5264) [47]. 
 
 
Fig. 11: Structure of compounds CT5102 (a), CT5263 (b), CT5264 (c), CT5269 (d) and CT5273 (e). 
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1.6.6. AZD0530 
This compound, known as sarcatinib (Fig. 12), is an orally available SFKs inhibitor. 
AZC0530 has demonstrated potent antimigratory and antiinvasive effects in vitro and 
it presents a good inhibitory activity against Fyn, with an IC50 of 10 nM [48]. 
 
Fig. 12: Structure of sarcatinib. 
1.6.7. BMS-354825 
This molecule, known as dasatinib (Fig. 13), is an exquisitely potent inhibitor of the 
Src family kinases. It is a highly potent ATP competitive inhibitor and the lack of 
selectivity  of this compound among Src family kinases is not unexpected, because 
the kinase domain is known to be highly conserved. It has subnanomolar IC50 against 
many kinases, as the case of Fyn (IC50 0.2 nM) [49].  
 
Fig. 13: Structure of dasatinib.  
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1.6.8. Compound 2 
This molecule (Fig. 14) is a potent inhibitor of SFKs that interacts with ATP binding 
site of kinases. Compound 2 has an excellent selectivity against the receptor tyrosine 
and serine/threonine kinases whereas no selectivity against Src family kinases is 
observed, presumably due to the high sequence homology within their ATP binding 
sites. This compound has an IC50 against Fyn of 1 nM [50].  
 
Fig. 14: Structure of compound 2. 
 
 
 
 
 
 
 
 
 
 
 
 
23 
 
2. Introduction to the experimental section 
 
The design of compounds synthetized during my thesis work started with virtual 
screening studies that identified new Fyn inhibitors. 
For this study, it was used a data set reported by Rohrer and Baumann in 2009 [51]. 
This data set is made up of 18 different databases of 15030 compounds (30 active and 
15000 decoy molecules) for 18 different targets and among them four targeted kinase 
enzymes. The decoy data set for cAMP-dependent protein kinase catalytic subunit 
alpha (PKA) was chosen because Fyn and PKA were very similar and the binding 
site is highly conserved with a percentage of identity of 71%. This database contains 
15020 compounds: 15000 PKA decoys and 20 selected Fyn inhibitors.  
Then, a FLAP database was created by processing  all templates and test compounds 
with the FLAP (Fingerprints for Ligands and Proteins) software, which provides 
ligand-based, receptor-based, and pharmacophore-based VS approaches. On this 
FLAP database, called Fyn-MUV, containing all the information required for 
calculation for each molecule, it was performed a screening by the different FLAP 
approaches . From this first analysis, 7564 compounds were selected and, therefore, 
taken into account.  
Then, the filtered database was subjected to docking studies and the docked 
molecules were classified using two scoring functions, Chemscore from Fred and 
Amberscore from Dock 6.0.  All the compounds that had scoring value in the range 
of the first 80% of the active molecules by both these scoring functions were 
considered to be active; 256 compounds were selected and then subjected to H-bond 
filter.  
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Analysing the X-ray complexes between Fyn and inhibitors binding the ATP binding 
site of the kinase, it was observed that the backbone nitrogen of M345 and the 
backbone oxygen of E343 and M345 were very important, since they form key 
hydrogen bonds with these inhibitors. All the compounds that did not form at least 
two H-bond interactions with these residues were rejected.  
The resulting 69 compounds were then subjected to a MD (molecular dynamic) 
simulation to verify the stability of the inhibitor-enzyme interactions. All the ligands, 
that maintained the H-bonds with the backbone atoms of E343 and M345 for at least 
90% of the whole MD simulation, were selected and taken into account.  
These considered 36 active compounds were clustered in eight classes on the basis of 
their central scaffold and, for each group a representative compound was chosen 
(Fig.15). 
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Fig.15 : Structures and Fyn inhibitory activities of the tested compounds.  
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These compounds were subjected to a Fyn inhibition assay using the reference Src 
inhibitor PP2 as positive control [52]. As indicated in Fig.15, five out of the eight 
compounds showed IC50 values ranging from 5 to 70 μM and, therefore, a good Fyn 
inhibitory activity.  
Through the X-ray analysis of the complex inhibitor-enzyme, it was possible to 
observe the interactions between Fyn and the five representative compounds (Fig.16). 
With regard to compound VS1, the 6- aminonicotinamide central scaffold forms two 
H-bonds with the backbone of M345 and an H-bond with the hydroxyl group of 
T342; the 3-chlorophenyl ring is directed toward the solvent-accessible region of the 
binding site and the antipodal 2-chlorophenyl interacts with V285 and the methyl 
group of T342 (Fig.16A).  
The quinolinone central scaffold of compound VS3 forms two H-bonds with the 
backbone of M345 and the indazole group forms a H-bond with the nitrogen 
backbone of D408 and interacts with V285 and L397 (Fig.16B).  
The pyrazolidine system of compound VS4 forms two H-bonds with the backbone 
M345; the indole ring interacts with V285, L397 and forms a H-bond with the 
hydroxyl group of T342. Finally, the phenyl ring is direct toward the solvent-
accessible region of the binding site (Fig. 16C). 
 With regard to compound VS6, the triazinone central scaffold interacts with the 
nitrogen backbone of M345 and the oxygen backbone of E343; the benzodioxole ring 
forms a H-bond with K299 and the amine function interacts, through a H-bond, with 
the hydroxyl group of T342 (Fig. 16D). 
 The triazole ring of compound VS8 forms a H-bond with the nitrogen backbone of 
M345 and with the oxygen backbone of E343; the substituted 2- pyrimidinamine 
group interacts with V285 and with the hydroxyl group of T342 (Fig. 16E).  
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Fig.16 : Minimized average structures of compounds VS1 (A), VS3 (B), VS4 (C), VS6 (D), and VS8 (E) 
docked into Fyn. The X-ray complex between Fyn and staurosporine is also reported as a reference system 
(F). 
Three of these compounds (VS3, VS4 and  VS6) were tested to evaluate their 
activities against different kinases. Compound VS3 did not show any activity against 
the tested kinases; compounds VS4 and VS6 showed a moderate activity against the 
Epidermal Growth Factor Receptor (EGFR) (Fig. 17). 
 
 
 
Fig. 17 : Percent kinase activity observed at 20 μM concentration of the tested compounds. Values are the 
average from two evaluations. Error bars indicate standard error of the mean. 
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Then these three compounds were tested on cell lines to evaluate their 
antiproliferative potency against tumour cells. The three selected cell lines were: two 
tumour cell lines, MDA-MB-231 (human breast carcinoma cells)and A549 (non-
small cell lung cancer) and the noncancerous MRC-5 cells (human fetal lung 
fibroblast). All the three compounds showed good inhibitory activity against the two 
tumour cell lines, with IC50 values ranging from 63 to 198 μM. Moreover, all the 
compounds did not showe activity against normal cells MRC-5 (Table. 1). 
 
 
Table 1. Cell Growth Inhibitory Activities (IC50) of Compounds VS3, VS4, VS6, and PP2 
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3. Results and discussion 
 
3.1.  Molecular design  
Considering the virtual screening studies reported in the previous chapter, it is clear 
that the presence of at least two hydrogen bonds between the inhibitor molecule and 
the binding site of Fyn kinase are necessary to inhibit the protein, and that these 
established interactions should be fairly stable.  
In particular, some specific bonds are important: 
 
 the H-bond with the backbone nitrogen of M345; 
 
 the H-bond with the backbone oxygen of E343 and M345. 
 
On the basis of the obtained results, we designed and synthesized new compounds 
that may be able to interact with the binding site of the enzyme and, therefore, to 
inhibit Fyn.  
During my thesis work, seven new molecules were synthesized with the aim of 
improving the inhibition activity on Fyn. The design of these compounds was 
inspired by the structure of compound VS6, which, among the molecules selected 
during the virtual screening tests, was the one that showed the best inhibitory activity 
against Fyn, with an IC50 of 4.8 μM.  
The structural modifications concern the introduction of various substituents on the 
two aromatic rings on the 1,2,4-triazin-5(4H)-one central scaffold (Fig.18). These 
compounds share the 1,2,4-triazin-5(4H)-one scaffold and present various groups that 
can behave as hydrogen-bonds acceptors such as methoxy, trifluoromethoxy, fluoro 
or methylenedioxy. These groups were introduced either in para or in meta position 
on the aromatic rings (Fig. 19).  
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Fig. 18: Structure of VS6 and general structure of compounds synthesized during my thesis work. 
  
 
 
 
 
Fig. 19: Structures of compounds synthesized during my thesis work. 
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3.2. Chemical synthesis 
These compounds were synthetized by adopting a previously reported synthetic 
strategy [53] (Scheme 1).  
 
 
 
 
Scheme. 1: General synthesis of Fyn inhibitors. 
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 The first step involves the formation of (Z)-4-benzylidene-2-phenyloxazol-5(4H)-
one; this compound is obtained from the Erlenmeyer-Plӧchl reaction, that is a 
cyclodehydration-condensation of the appropriate aldehyde (in this case 
benzaldehyde or p-fluorobenzaldehyde) and hippuric acid in acetic anhydride 
catalysed by the acetate anion of potassium acetate which was used as the base 
(Scheme 2). 
 
 
Scheme 2: Synthesis of 5-oxazolones. 
 
 
In detail (Scheme 3) [54], the oxygen atom of hydroxyl group of hippuric acid 
attacks the carbonyl carbon of acetic anhydride with the elimination of a molecule of 
acetic acid. After keto-enol tautomerism, a further attack of compound c on the 
aromatic aldehyde takes place, in such a way that compound d is obtained. 
Subsequently, a molecule of water is eliminated and a new keto-enolic equilibrium is 
formed; the enol form (compound f) gives cyclization obtaining compound g. In the 
last step, a molecule of acetic acid is eliminated and the desired oxazolone is formed 
(compound 8 or 9). 
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Scheme 3: Mechanism of Erlenmeyer-Plӧchl reaction. 
 
Initially, the crude compound was purified through a chromatographic column, using 
as eluent, a mixture of n-hexane and AcOEt; in this way, we were able to separate the 
reaction product from the unreacted benzaldehyde.  Because the obtained product 
needed large volume of solvents to be completely eluted, we tried to purify this 
product by simply washing the crude precipitate with distilled hexane to remove the 
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starting material benzaldehyde. This method proved to be efficacious since it was 
possible to get the pure product with comparable yields, optimizing the working time 
and solvent consumption/disposal.  
The second step of the synthetic strategy (Scheme 4) is divided into two parts.  
 
 
 
Scheme 4: The second step of the synthetic strategy 
 
 
In the first part, the oxazolone reacts with aqueous KOH; in this way, the lactone ring 
is opened with the anion formation of the corresponding hydroxy acid (compound b) 
which is in keto-enolic equilibrium with compound c (Scheme 5). The amide bond of 
compound d is then hydrolyzed with formation of compound e; the latter is in keto-
35 
 
enolic equilibrium with compound f. The subsequent hydrolysis of the imine group 
leads to the formation of compound h. 
 
 
 
Scheme 5: Base-catalyzed hydrolysis of oxazolones. 
 
 
After the acidification with acetic acid, in the second part of this step, the formed 
intermediate reacts with variously substituted 4-aryl thiosemicarbazide. In detail 
(Scheme 6), compound h is protonated by acetic acid forming compound i, an α keto 
acid which reacts with 4-arylthiosemicarbazide; in this way compound l is formed. 
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Subsequently, two water molecules are released by the cyclization of compound m 
and formation of compounds 10-16. 
 
 
 
 
Scheme 6: Formation of compounds 10-16 from intermediate m with variously substituted 4-
arylthiosemicarbazides. 
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Scheme 7 shows the subsequent methylation of the compounds 10-16 with CH3I in 
CH3ONa/CH3OH.  
 
 
Scheme 7: Methylation of compounds 10-16.  
 
This reaction was monitored by thin-layer chromatographic (TLC) and it was 
observed the formation of two reaction products with slightly different Rf (retention 
factor). 
The two compounds, 1 and 2, were separated and isolated by a chromatographic 
column, using as eluent a mixture of n-hexane and AcOEt, and subsequently they 
were analysed by 
1
H-NMR spectroscopy. The two spectra were very similar, 
differing only in the singlet position due to CH3 (2.54 ppm in the spectrum of 
compound 1 and 4.00 ppm in that of compound 2).  The two compounds were 
produced with comparable yields and, given the short duration of the reaction (only 
15 minutes), probably they formed simultaneously.  
We have proposed three possible structures of the two reaction compounds (Fig.20).    
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Fig. 20: Possible structures of compounds formed during methylation.  
 
 
Compound A, in which the sulphur atom is methylated, is the desired compound; in 
the compound B, the oxygen atom is methylated and in the compound C methylation 
occurs on the nitrogen atom.  
In order to confirm the hypothesized structures, the two compounds were also 
analysed by IR spectroscopy (Fig. 21). By means of this analysis we hoped to 
observe the obvious differences between the spectra, such as the absence of the peak 
due to stretching the C=O group if one of the two compound, 1 or 2, was methylated 
on carbonyl oxygen (structure B). Strong IR absorptions at 1680-1690 cm
-1
 were 
present in both compounds, thus suggesting that they are more likely represented by 
structures A and C (Fig. 20).  
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Fig. 21: IR spectra of the products of the methylation.  
 
40 
 
Both the isolated compounds were reacted with hydrazine in isopropanol, in the next 
step of the synthetic strategy (Scheme 8).  
 
 
 
 
Scheme 8: Reaction of compounds 17-23 with hydrazine in Isopropyl alcohol. 
 
We expected that only one of the two compounds could react (structure A), giving the 
formation of the desired product. 
The products obtained from these two parallel reactions were independently analysed 
by 
1
H-NMR spectroscopy and we observed that the two spectra coincided. Both the 
compounds, therefore, reacted with hydrazine forming the same product (Fig.22). 
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Fig. 22: General structure obtained by the reaction of compound 1 and 2 with hydrazine in isopropanol. 
 
The Scheme 8 shows the conditions under which this reaction occurs. In this case, 
compounds 17-23 were submitted to a rearrangement step in the presence of 
hydrazine in isopropanol to get derivatives 24-30. 
In the next step, that is the final step of synthetic strategy, the compounds 24-30 were 
reacted with NaNO2 and concentrated hydrochloric acid in EtOH. (Scheme 9) 
It is a reaction of deamination with N2 release and formation of the final compounds 
1- 7. 
 
 
 
 
Scheme 9: Final step of the synthesis. 
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During my work in the laboratory, I also synthetized hippuric acid (starting 
compound of the synthetic strategy) and the differently substituted 4-phenyl 
thiosemicarbazides, necessary in the second step of the synthetic route, that were not 
commercially available.  
For the synthesis of hippuric acid (benzoyl glycine), glycine is reacted with benzoyl 
chloride in the presence of NaOH 10% (Scheme 10). 
 
 
 
 
Scheme 10: Synthesis of Hippuric acid.  
 
This reaction is known as “Schotten-Baumann” reaction and the mechanism is shown 
in Scheme 11. 
 
Scheme 11: Mechanism of reaction of the Schotten – Baumann reaction. 
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The Schotten-Baumann reaction is an reaction used to convert an acyl halide to an 
amide if reacted with an amine and base. The reaction begins with the nitrogen 
attacking the carbonyl carbon of the acyl halide which rearranges eliminating the 
chlorine atom. Deprotonation by the base then provides the final amide product 
(compound c). 
In our case, the reaction product is then acidified with concentrated hydrochloric acid 
to protonate the carboxylic acid group and the hippuric acid is obtained. 
Finally, for the synthesis of variously substituted 4-phenyl thiosemicarbazides (which 
were required in the second step of the synthetic pathway), the corresponding 
isothiocyanate was reacted with hydrazine in the presence of isopropanol (Scheme 
12). It is a reaction rather fast because the duration is of just one hour. 
 
 
 
 
 
Scheme 12: Synthesis of variously substituted 4-phenyl thiosemicarbazides.  
 
For the synthesis of compound 40, the starting isothiocyanate was not commercially 
available, thus it was synthesized starting from 3,4-methylenedioxy aniline.  
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Aniline is reacted with CS2 and Et3N in the presence of di-tert-butyl dicarbonate 
(Boc2O) and 4-dimethylaminopyridine (DMAP) in EtOH (Scheme 13). 
 
 
 
Scheme 13: Synthesis of 3,4-methylenedioxy isothiocynate 
 
As shown in the Scheme 14 [55], initially aniline reacts with CS2 forming the 
dithiocarbamate, which in a second moment, reacts with Boc2O to form CO2 and an 
unstable adduct that rapidly decomposes giving isothiocyanate 35. 
The presence of triethylamine is necessary for the stabilisation and complete 
formation of the dithiocarbamate. 
 
 
Scheme 14: Mechanism for the base-catalysed synthesis of isothiocyanates from the corresponding amines 
using di-tert-butyl dicarbonate. 
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The compound 35, as is shown in the Scheme 12, is reacted with hydrazine in 
isopropanol, thus obtaining the desired thiosemicarbazide (Compound 40). 
During my thesis work, I tried to synthetize also a series of compounds in which the 
starting compound was the oxazolone bearing a methyl group on the exocyclic 
double bond, resulting from reaction of hippuric acid and acetaldehyde on the 
condition of the Erlenmeyer-Plӧchl reaction. (Scheme 15) 
 
 
 
Scheme 15: Erlenmeyer- Plӧchl reaction with acetaldehyde. 
 
 
This reaction was repeated several times; the first time, we performed a classic 
reaction work-up with water and AcOEt and then all the various products present in 
the reaction mixture were isolated, using a chromatographic column. These 
compounds were analysed by 
1
H-NMR spectrometry and we did not obtain the 
desired product (compound 41).   
In another attempt, I added EtOH to the reaction mixture, it formed an orange 
precipitate which was then filtered and analyzed by 
1
H-NMR spectrometry, but 
unfortunately it did not correspond to the desired compound.  
At present, the reasons why this reaction was not successful were not further 
investigated.  
In the last part of my thesis work, I synthetized on a large scale  compounds1 and 24 
(Fig. 23) to perform a crystallization on the pure products. These two compounds 
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were selected considering the good total yield of the synthesis of compound 1 (21 %), 
compared to the other synthesized compounds (7-18 %). 
 
 
Fig. 23: Structure of crystallized compounds. 
 
The crystallization of compound 24 was conducted in CHCl3. The compound was 
dissolved in a minimum volume of hot CHCl3 and then the obtained solution was 
cooled slowly. 
In the other case, compound 1 was dissolved in a minimal amount of hot AcOEt and 
then, the flask containing the solution was placed in a container in which it was 
present hexane.  
In both cases, I obtained white crystalline aggregates in which the single crystals 
were aggregated in radial disposition (Fig. 24). 
These crystals will be subjected to X-ray analysis in order to confirm their structures.   
 
 
Fig.24: Crystalline aggregates obtained from the crystallization of compound 1. 
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4. Summary and conclusions 
 
Fyn is a non-receptor tyrosine kinase, belonging to the Src family kinases (SFKs).  
This protein plays a key role in several transduction pathways in physiological and 
pathological situations. Fyn is implicated in brain development processes, such as 
myelination, differentiation of oligodendrocytes and synapses formation. Several 
lines of evidence implicate Fyn in the Alzheimer’s disease (AD) and other 
tauopathies. In fact, Fyn phosphorylates Tau protein (a microtubule-associated 
protein) at Tyr18. Tyrosine-phosphorylated Tau is one of the main components 
present in the tangles that are characteristic of AD brain. Moreover, Fyn mediates 
Aβ-induced synaptic deficit and neurotoxicity and is activated by Aβ oligomers, 
causing synaptic and cognitive impairment.  
Fyn also takes part in numerous cellular functions such as growth and cell 
proliferation, morphogenesis and cell motility. Fyn overexpression determines an 
increase in cell growth, cell proliferation and cell motility favouring the formation 
and development of cancer and metastasis.  
Since Fyn overexpression is widely involved in many diseases, this protein is an 
important pharmaceutical target taken into account especially for the treatment of 
neurodegenerative diseases and cancers.  
Although there are not selective inhibitors for Fyn in the literature, several molecules, 
such as staurosporine, PP1 and PP2, dasatinib and saracatinib, are known to be able 
to inhibit this protein by interacting with its catalytic site..  
Virtual screening studies showed that key-interactions with two residues (E343 and 
M345), which are present in the catalytic site of this kinase, are required to have a 
good inhibitory activity.   
During my thesis work, I have synthesized seven molecules that share the same 1,2,4-
triazin-5-(2H)-one scaffold, differing for some substitutions in the aryl rings (R1 and 
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R2, Fig.25). The design of these compounds was inspired from the structure of a 
compound identified as a good Fyn inhibitor by virtual screening studies. 
 
 
 
 
 
Fig.25: General structure of the synthesized compounds 
 
The first step of the synthetic strategy was the reaction of an appropriate aldehyde 
(benzaldehyde or p-fluorobenzaldehyde) with hippuric acid in acetic anhydride and in 
presence of potassium acetate (Erlenmeyer-Plӧchl reaction). This step led to the 
formation of (Z)-4-benzylidene-2-phenyloxazol-5(4H)-one. In the second step, 
oxazolone was submitted to a base-catalysed hydrolysis and then, the formed 
intermediate reacted with variously substituted 4-phenyl thiosemicarbazides. The 
compounds obtained in this step were then methylated with CH3I in CH3ONa/ 
CH3OH and subsequently, the products of methylation were submitted to a 
rearrangement in presence of hydrazine in isopropanol alcohol. The final step was a 
deamination in presence of NaNO2 and concentrated hydrochloric acid in EtOH. This 
reaction led to the formation of final compounds.  
The final products are currently being evaluated for Fyn inhibitory activity. These 
assays will determine which are the compounds with the best inhibitory activity 
against Fyn, and therefore, the substituents which best interact with the binding site 
of the protein. 
Considering studies of molecular modelling conducted on the molecule that has 
inspired the structure of the compounds synthesized during my thesis work (VS6), it 
was observed that this molecule, in addition to its interaction with E343 and M345, 
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also forms a H-bond with K299. In the formation of this bond, the benzodioxole ring 
of  VS6 behaves as an H bond acceptor. Therefore,once the screening results will be 
available for this first series of compounds, this project will continue with the 
synthesis of a new series of compounds containing  the R2 substituent that will prove 
to be the most suitable H bond acceptor, together with a differentiation in position 5, 
where variously substituted aryl or heteroaromatic rings can be linked to the central 
scaffold by a methylene or a –NH- moiety (Fig.26).  
 
 
 
 
Fig.26: VS6 and general structures of the hypothesized compounds for the future project 
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5. Experimental procedures 
 
Materials and methods  
 
All reactions performed during my thesis work were monitored by thin-layer 
chromatographic (TLC) using Merck aluminium silica gel (60 F254) sheets which 
were observed under a UV lamp (254 nm). 
 Anhydrous sodium sulfate was used to dry the organic phases obtained from 
treatment of various reactions.  
Crude compounds were purified by column chromatography that was performed 
using silica gel 60 (0.040- 0.063 mm; Merck).  
Finally, to confirm the structure of all the reaction intermediates and final products it 
was used nuclear magnetic resonance spectrometry; NMR spectra were obtained with 
a Bruker Avance III HD operating at 400 Hz and relative to the solvent signal. 
Chemical shifts are reported in parts per million (ppm) and coupling constants (J) in 
Hz. The multiplicities were explained using the following abbreviations:   s = singlet, 
d = doublet, m = multiplet, q = quartet, dd = double doublet, tt = triple triplet, bs = 
broad singlet. 
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Hippuric acid 
 
 
 
Benzoyl chloride (1.8 ml, 15.3 mmol) was added to a solution of glycine (1000 mg, 
13.32 mmol) in NaOH 10% (9.99 ml) in a single-neck round bottom flask. The 
mixture was stirred at room temperature for 1h and it formed a white precipitate.  
The reaction product was poured in a beaker containing ice and then was acidified 
with HCl conc. . The crude product was filtered, washed with CHCl3 and cold water 
and dried under reduced pressure. It was obtained a white solid (hippuric acid, 1.854 
g, 10.35 mmol) with a yield of 78 %. 
 
 
1
H  NMR  (DMSO-d6)  δ  ppm: 
3.92 (d, 2H, J= 5.9; 7.46- 7.51 (m, 2H); 7.54 (tt; 1H, J= 7.3, 1.3); 7.87 (AA’XX’, 
2H, JAX= 8.2, JAA’/XX’= 1.8); 8.83 (t, 1H, J= 5.8) 
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8 
 
 
 
Under argon atmosphere, benzaldehyde (0.96 ml, 9.42 mmol), acetic anhydride (2.66 
ml 28.26 mmol), hippuric acid (1.688 g, 9.42 mmol) and potassium acetate ( 924.6 
mg, 9.42 mmol) were inserted in a flame-dried double-necked round flask. After 
adding potassium acetate, it formed an orange solution. The mixture was refluxed at 
90 °C for 2 h. After cooling at RT, the crude mixture was extracted with AcOEt. The 
organic phase was dried and concentrated. The crude product was purified with 
chromatography column in silica gel (n-Hexane/ AcOEt 95:5) to afford compound 8 
(1.830 g, 7.34 mmol) as yellow, voluminous solid with a yield of 78%. 
 
1
H NMR (CDCl3) δ (ppm): 
7.27(s, 1H); 7.45-7.57 (m, 5H);  7.62 (tt, 1H, J= 7.4, 1.4 Hz );  8.19-8.23 (m, 4H) 
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10 
 
 
 
To the compound 8 (500 mg, 2.01 mmol) in a two-necked round bottomed flask, a 
solution of KOH 1M (6.03 ml, 6.03 mmol) was added. The mixture was refluxed at 
115 °C for 4 h. After cooling at room temperature, it was acidified, in an ice bath,  
with acetic acid. Then 4-phenyl-thiosemicarbazide (335.3 mg, 2.01 mmol) in EtOH 
(6.03ml) was added. The resulting solution was stirred and refluxed at 105 °C for 5h. 
The reaction mixture was extracted with AcOEt. The organic phase was dried and 
evaporated under reduced pressure. The crude product was purified by a column 
chromatography in silica gel (n-Hexane / AcOEt 85:15) to afford compound 10 
(286.8 mg, 0.97 mmol) as a white/ yellow solid with a yield of 48%. 
 
1
H NMR (CDCl3) δ ppm: 
3.98 (s, 2H); 7.18-7.21 (m, 2H); 7.27- 7.37 (m, 5H);  7.46-7.55 (m, 3H); 10.31 (bs, 
1H) 
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17 
 
 
 
A solution of compound 10 (100 mg, 0.338 mmol) in CH3OH (0.4 ml) under argon 
was cooled and treated with a solution of CH3ONa/CH3OH (0.08 ml, 0.338 mmol). 
Then CH3I (0.02 ml, 0.350 mmol) was added and the resulting mixture was stirred at 
room temperature for 15’. The crude solution was evaporated and purified with 
chromatography column in silica gel ( n-Hexane/ AcOEt  85:15)  
 
1
H NMR  (CDCl3) δ ppm: 
2.54 (s, 3H); 4.16 (s, 2H); 7.20- 7.25 (m, 3H); 7.28-7.33 (m, 2H); 7.43-7.46 (m, 2H); 
7.51-7.55 (m, 3H)  
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24 
 
 
 
 
To a stirred solution of compound 17 (479.6 mg, 1.55 mmol) in isopropyl alcohol 
(5.46 ml) in a flame-dried two-necked round bottomed flask, hydrazine (1.09 ml) was 
added under argon atmosphere. The resulting mixture was refluxed at 105°C for 3h. 
After cooling at RT, the crude solution was dried, concentrated and purified with a 
silica gel column (n-Hexane / AcOEt 6:4) to afford compound 24 (200 mg, 0.682 
mmol) as a white-yellow solid. The yield of this reaction was 44%. 
 
1
H NMR (CDCl3) δ ppm: 
4.11 (s, 2H); 4.63 (bs, 1H); 7.12- 7.17 (m, 1H);  7.19- 7.24 (m, 1H); 7.28-7.31 (m, 
2H); 7.34-7.39 (m, 2H); 7.40-7.43 (m, 2H); 7.65-7.69 (m, 2H) 
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Compound 24 (121.7 mg, 0.415 mmol ) was dissolved, under inert atmosphere, in 
EtOH (6.08 ml). To resulting solution, concentrated hydrochloric acid (1.22 ml) was 
dropwise added in an ice bath. Finally, cold NaNO2 10% (3.04 ml) was added and the 
mixture was stirred, at room temperature, overnight. The reaction mixture was 
extracted with AcOEt and the organic phase was dried and evaporated. The crude 
product was purified with chromatography column in silica gel (CH3Cl / CH3OH  
98:2) to afford a compound 1 (78 mg, 0.280 mmol) as a white, voluminous solid with 
a yield of 68%.  
 
1
H  NMR  (DMSO-d6)  δ ppm: 
3.81 (s, 2H); 7.08 (tt, 1H, J= 7.4, 2.0);  7.17-7.22 (m, 1H); 7.25-7.29 (m, 4H);  7.30-
7.35 (m, 2H); 7.47-7.51 (m, 2H);  9.24 (bs, 1H); 12.07 (bs, 1H) 
 
13
C  NMR  (DMSO-d6)  δ ppm:  
35.92; 121.24 (2C); 123.55 ; 126.23 ; 128.22 (2C); 128.72 (2 C); 129.05 (2C); 137.55 
; 137.70 ; 148.80 ; 153.46 ; 162.35  
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37 
 
 
 
 
A solution of NH2NH2 hydrate (0.16 ml, 5.09 mmol) in isopropyl alcohol (40 ml) was 
stirred in a flame-dried two-necked flask, under inert atmosphere. Then, 4-
methoxyphenyl isothiocyanate (0.59 ml, 4.24 mmol) was added. Once the addiction 
was completed, stirring was continued for 1h at room temperature. The crude product 
was purified by a filtration with a glass septum. Finally, the white solid obtained 
(compound 37, 747.4 mg, 3.79 mmol) was dried under reduced pressure. The yield of 
this reaction was 89%. 
 
1
H NMR (DMSO-d6) δ ppm: 
3.73 (s, 3H);  4.70 (bs, 2H);  6.84-6.88 (m, 2H);  7.43-7.46 (m, 2H); 8.97 (bs, 1H); 
9.49 (bs, 1H) 
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11 
 
 
 
To the compound 8 ( 631.8 mg, 2.53 mmol) in a two-necked round bottomed flask, a 
solution of KOH 1M (7.59 ml, 7.59 mmol) was added. The mixture was refluxed at 
115 °C for 4h. After cooling at room temperature, it was acidified, in an ice bath,  
with acetic acid. Then, compound 37 (500 mg, 2.53 mmol) in EtOH (7.59 ml) was 
added. The resulting solution was stirred and refluxed at 105 °C for 5 h. The reaction 
mixture was extracted with AcOEt . The organic phase was dried and evaporated 
under reduced pressure. The crude product was purified by a column chromatography 
in silica gel (n-Hexane / AcOEt 85:15) to afford compound 11 (223.9 mg, 0.683 
mmol) as a yellow solid with a yield of 27%. 
 
1 
H  NMR (CDCl3) δ ppm: 
3.84 (s, 3H);  3.97 (s, 2H);  7.01 (AA’XX’, 2H, JAX= 9, JAA’/XX’= 2.7); 7.08-7.12 (m, 
2H); 7.25-7.36 (m, 5H); 10.35 (bs, 1H) 
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A solution of compound 11  (223.9 mg, 0.688 mmol) in CH3OH (0.69 ml) under 
argon was cooled and treated with a solution of CH3ONa/CH3OH (0.16 ml, 0.688 
mmol). Then CH3I (0.05 ml, 0.712 mmol) was added and the resulting mixture was 
stirred at room temperature for 15’. The crude solution was evaporated and was used 
in the next step without any further purification.  
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To a stirred solution of compound 18 (233.49 mg, 0.688 mmol) in isopropyl alcohol 
(5.00 ml) in a flame-dried two-necked round bottomed flask, hydrazine (0.48 ml) was 
added under argon atmosphere. The resulting mixture was refluxed at 105 °C for 3 h. 
After cooling at RT, the crude solution was dried, concentrated and purified with a 
silica gel column (n-Hexane / AcOEt 6:4) to afford compound 25 (60 mg, 0.186 
mmol) as a white-yellow solid. The yield of this reaction was 27%. 
 
1
H  NMR (CDCl3)  δ ppm: 
3.80 (s, 3H);  4.09 (s, 2H);  6.87-6.91 (m, 2H);  7.18- 7.23 (m, 1H);  7.27-7.32 (m, 
2H);  7.39-7.42 (m, 2H); 7.51-7.56 (m, 2H) 
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Compound 25 (60.0 mg, 0.186 mmol ) was dissolved, under inert atmosphere, in 
EtOH (3.00 ml). To resulting solution, concentrated hydrochloric acid (0.60 ml) was 
dropwise added in an ice bath. Finally, cold NaNO2 10% (1.50 ml) was added and the 
mixture was stirred, at room temperature, overnight. The reaction mixture was 
extracted with AcOEt and the organic phase was dried and evaporated. The crude 
product was purified with two chromatography columns in silica gel: the first (CH3Cl 
/ CH3OH  98:2) and the second (n-Hexane / AcOEt 3:7)  to afford a compound 2 
(32.7 mg, 0.108 mmol) as a white-yellow solid with a yield of 58%. 
 
1H  NMR (DMSO)  δ ppm: 
3.73 (s, 3H);  3.79 (s, 2H); 6.90 (AA’XX’, 2H, JAX= 9, JAA’/XX’= 2.9); 7.17- 7.21 (m, 
1H); 7.24- 7.30 (m, 4H); 7.34 (AA’XX’, 2H, JAX= 8.9, JAA/’XX’= 2.7); 9.02 (bs, 1H); 
11.98 (bs, 1H)  
 
13
C  NMR  (DMSO-d6)  δ ppm: 
35.88 ; 55.25 ; 113.77 ; 114.01 ( 2C);  120.52 ; 123.98 ; 126.20 ; 128.20 ; 129.04 ( 
2C); 130.11 ;  137.65 ; 148.57 ; 153.82 ; 156.08 ; 162.46  
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Under argon atmosphere,4-fluorobenzaldehyde (1.11 ml, 10.32 mmol), acetic 
anhydride (2.92 ml, 30.96 mmol), hippuric acid (1850 mg, 10.32 mmol) and 
potassium acetate (1013 mg, 10.32 mmol) were inserted in a flame-dried double-
necked round flask. The mixture was refluxed at 90 °C for  2h. After cooling at RT, 
the crude mixture was extracted with AcOEt. The organic phase was dried and 
concentrated. The crude product was purified by washing with distilled Hexane and 
was obtained the compound 9 (2.28 mg, 8.30 mmol) as a yellow, voluminous solid. 
The yield of this reaction was 80%. 
 
1
H  NMR (CDCl3)  δ ppm: 
7.18 (double AA’XX’, 2H, JAX= 8.6, JAA’/XX’= 2.5, JHF-o= 9.6); 7.22 (s, 1H);  7.52-
7.57 (m, 2H); 7.63 (tt, J= 7.4, 1.2); 8.17-8.21 (m, 2H); 8.25 (double AA’XX’, 2H, 
JAX= 9; JAA’/XX’= 2.5, JHF-m= 5.4) 
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To the compound 9 (935 mg, 3.50 mmol) in a two-necked round bottomed flask, a 
solution of KOH 1M (10.49 ml, 10.49 mmol) was added. The mixture was refluxed at 
115 °C for 4h. After cooling at room temperature, it was acidified, in an ice bath,  
with acetic acid. Then 4-phenyl thiosemicarbazide (585.3 mg, 3.50 mmol) in EtOH 
(10.49 ml) was added. The resulting solution was stirred and refluxed at 105°C for 
5h. The reaction mixture was extracted with AcOEt . The organic phase was dried 
and evaporated under reduced pressure. The crude product was purified by a column 
chromatography in silica gel (n-Hexane / AcOEt 9:1) to afford compound 12 (610.3 
mg, 1.95 mmol) as a glassy solid with a yield of 55%. 
 
1
H  NMR (CDCl3)  δ ppm: 
3.94 (s,2H); 7.01 (double AA’XX’, 2H, JAX= 8.6, JAA’/XX’= 2.5, JHF-o= 9.5); 7.16-7.20 
(m, 2H); 7.31 (double AA’XX’, 2H, JAX= 8.6, JAA’/XX’= 2.6, JHF-m= 5.4); 7.46-7.56 
(m, 3H); 10.35 (bs, 1H) 
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A solution of compound 12  (280 mg, 0.894 mmol) in CH3OH (0.89 ml) under argon 
was cooled and treated with a solution of CH3ONa/CH3OH (0.21 ml, 0.894 mmol). 
Then CH3I (0.06 ml, 0.926 mmol) was added and the resulting mixture was stirred at 
room temperature for 15’. The crude solution was evaporated and was used in the 
next step without any further purification. 
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26 
 
 
 
To a stirred solution of compound 19 (292.7 mg, 0.894 mmol) in isopropyl alcohol 
(3.15 ml) in a flame-dried two-necked round bottomed flask, hydrazine (0.63 ml) was 
added under argon atmosphere. The resulting mixture was refluxed at 105 °C for 3 h. 
After cooling at RT, the crude solution was dried, concentrated and purified with a 
silica gel column (n-Hexane / AcOEt 7:3) to afford  compound 26 (79.7 mg, 0.256 
mmol) as a white-yellow solid. The yield of this reaction was 29%. 
 
1
H  NMR (CDCl3)  δ ppm: 
4.05 (s, 2H);  6.95- 6.99 (m, 2H); 7.16- 7.21 (m, 1H); 7.34-7.40 (m, 4H);  7.60-7.63 
(m,2H) 
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Compound 26 (79.9 mg, 0.256 mmol) was dissolved, under inert atmosphere, in 
EtOH (3.98 ml). To resulting solution, concentrated hydrochloric acid (0.80 ml) was 
dropwise added in an ice bath. Finally, cold NaNO2 10% (1.99 ml) was added and 
the mixture was stirred, at room temperature, overnight. The reaction mixture was 
extracted with AcOEt and the organic phase was dried and evaporated. The crude 
product was purified by chromatography column in silica gel (CHCl3 / CH3OH 98:2) 
to afford compound 3 (23.8 mg, 0.080 mmol) as a white solid with a yield of 31%. 
 
1
H  NMR (DMSO-d6)  δ ppm: 
3.80 (s, 2H); 7.06- 7.13 (m,3H);  7.28- 7.35 (m, 4H);  7.47- 7.50 (m, 2H);  9.23 (bs, 
1H);  12.06 (bs, 1H)  
 
13
C  NMR  (DMSO-d6)  δ ppm: 
35.09 ; 114.86 (d, 2C, J= 21.1); 121.28 ; 123.58 ; 128.70 (3C); 130.73 (d, 2C, J= 
8.0); 133.56 (d, 2C, J= 3.0); 137.61 ; 148.67 ; 153.41 ; 160.91 (d, 1C, J= 242.3) 
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13 
 
 
 
To the compound 9 (935 mg, 3.50 mmol) in a two-necked round bottomed flask, a 
solution of KOH 1M (10.49 ml, 10.49 mmol) was added. The mixture was refluxed at 
115 °C for 4 h. After cooling at room temperature, it was acidified, in an ice bath,  
with acetic acid. Then compound 37 (690.48 mg, 3.50 mmol) in EtOH (10.49 ml) 
was added. The resulting solution was stirred and refluxed at 105 °C for 5 h. The 
reaction mixture was extracted with AcOEt . The organic phase was dried and 
evaporated under reduced pressure. The crude product was purified by a column 
chromatography in silica gel (n-Hexane / AcOEt  85:15) to afford compound 13 
(548.6 mg, 1.60 mmol) as a white / yellow solid with a yield of 46%. 
 
1
H  NMR (CDCl3)  δ ppm: 
3.84 (s, 3H);  3.94 (s, 2H);  6.98 - 7.03 (m, 4H); 7.09 - 7.12 (m, 2H); 7.29- 7.33 (m, 
2H) 
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A solution of compound 13  (350 mg, 1.02 mmol) in CH3 OH (1.02 ml) under argon 
was cooled and treated with a solution of CH3 ONa/CH3 OH (0.24 ml, 1.02 mmol). 
After CH3 I (0.07 ml, 1.06 mmol) was added and the resulting mixture was stirred at 
room temperature for 15’. The crude solution was evaporated and was used in the 
next step without any further purification. 
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To a stirred solution of compound 20 (364.6 mg, 1.02 mmol) in isopropyl alcohol 
(3.59 ml) in a flame-dried two-necked round bottomed flask, hydrazine (0.72 ml) was 
added under argon atmosphere. The resulting mixture was refluxed at 105 °C for 3 h. 
After cooling at RT, the crude solution was dried, concentrated and purified with a 
silica gel column (n-Hexane / AcOEt 65:35) to afford  compound 27 (112.6 mg, 
0.330 mmol) as a white-yellow solid. The yield of this reaction was 32%. 
 
1 
H  NMR  (CDCl3) δ ppm: 
3.79 (s, 3H);  4.03 (s, 2H); 6.86- 6.90 (m, 2H); 6.94- 6.99 (m, 2H); 7.34 (double 
AA’XX’, 2H, JAX= 8.6, JAA’/XX’= 2.0, JHF-m= 5.4); 7.46- 7.49 (m, 2H) 
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Compound 27 (112.6 mg, 0.330 mmol) was dissolved, under inert atmosphere, in 
EtOH (5.63 ml). To resulting solution, concentrated hydrochloric acid (1.13 ml) was 
dropwise added in an ice bath. Finally cold NaNO2 10% (2.82 ml) was added and the 
mixture was stirred, at room temperature, overnight. The reaction mixture was 
extracted with AcOEt and the organic phase was dried and evaporated. The crude 
product was purified by chromatography column in silica gel (CH2Cl2 / CH3OH 98:2; 
95:5) to afford compound 4 (58.5 mg, 0.179 mmol) as a white solid with a yield of 
54%. 
 
1 
H  NMR  (DMSO-d6)  δ ppm: 
3.73 (s, 3H);  3.78 (s, 2H); 6.90 (AA’XX’, 2H, JAX= 9.1, JAA’/XX’= 2.9); 7.1 (double 
AA’XX’, 2H, JAX= 9.0, JAA’/XX’= 2.9, JHF-o= 9.6); 7.29 (double AA’XX’, 2H, JAX= 
8.8, JAA’/XX’= 2.4,  JHF-m= 5.6); 7.33 (AA’XX’, 2H, JAX= 9.0, JAA’/XX’= 2.8) 
 
13
C  NMR  (DMSO-d6)  δ  ppm: 
35.08; 55.24; 114.01 (2C); 114.86 (d, 2C, J= 21.3); 124.01 (2C); 125.41; 130.06; 
130.87 (d, 2C, J= 8.0); 133.68 (d, J= 3.0); 148.43; 153.80; 156.11; 160.92 (d, J= 
240.5)   
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A solution  of NH2 NH2  hydrate (0.08 ml, 2.74 mmol) in isopropyl alcohol (22.8 ml) 
was stirred in a flame-dried two-necked flask, under inert atmosphere. Then, 4-
trifluoromethoxy phenyl isothiocyanate (0.37 ml, 2.28 mmol) was added. Once  the 
addiction was completed, stirring was continued for 1h at room temperature. The 
crude product was purified by a filtration with a glass septum. Finally, the white solid 
obtained (compound 38, 558.8 mg, 2.07 mmol) was dried under reduced pressure. 
The yield of this reaction was 91%. 
 
1 
H  NMR  (DMSO-d6)  δ ppm: 
4.96 (bs, 2H); 7.28- 7.30 (m, 2H); 7.76- 7.78 (m, 2H); 9.24 (bs, 1H) 
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To the compound 9 (552.6 mg, 2.06 mmol) in a two-necked round bottomed flask, a 
solution of KOH 1M (6.20 ml, 6.20 mmol) was added. The mixture was refluxed at 
115°C for 4h. After cooling at room temperature, it was acidified, in an ice bath,  
with acetic acid. Then compound 38 (558.8 mg, 2.06 mmol) in EtOH (6.20 ml) was 
added. The resulting solution was stirred and refluxed at 105 °C for 5 h. The reaction 
mixture was extracted with AcOEt . The organic phase was dried and evaporated 
under reduced pressure. The crude product was purified by a column chromatography 
in silica gel (n-Hexane / AcOEt  85:15) to afford compound 14 (550.6 mg, 1.39 
mmol) as an orange solid with a yield of 67%. 
 
1 
H  NMR  (CDCl3)  δ ppm: 
3.94 (s, 2H); 6.99- 7.03 (m, 2H); 7.21- 7.26 (m, 2H); 7.30 (double AA’XX’, 2H, JAX= 
8.8, JAA’/XX’= 2.4,  JHF-m= 5.2); 10.45 (bs, 1H) 
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A solution of compound 14  (100 mg, 0.25 mmol) in CH3 OH (0.25 ml) under argon 
was cooled and treated with a solution of CH3ONa/CH3OH (0.06 ml, 0.25 mmol). 
Then CH3I (0.02 ml, 0.26 mmol) was added and the resulting mixture was stirred at 
room temperature for 15’. The crude solution was evaporated and was used in the 
next step without any further purification. 
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To a stirred solution of compound 21 (464.88 mg, 1.13 mmol) in isopropyl alcohol 
(3.98 ml) in a flame-dried two-necked round bottomed flask, hydrazine (0.80 ml) was 
added under argon atmosphere. The resulting mixture was refluxed at 105 °C for 3 h. 
After cooling at RT, the crude solution was dried, concentrated and purified with a 
silica gel column (n-Hexane / AcOEt 8:2; 7:3) to afford  compound 28 (132.4 mg, 
0.335 mmol) as a yellow solid. The yield of this reaction was 30%. 
 
1 
H  NMR (CDCl3)  δ ppm: 
4.07 (s, 2H); 6.94- 6.98 (m, 2H); 7.20- 7.23 (m, 2H); 7.37 (double AA’XX’, 2H, JAX= 
8.5, JAA’/XX’= 2.4,  JHF-m= 5.4); 7.67- 7.71 (m, 2H) 
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Compound 28 (132.4 mg, 0.335 mmol) was dissolved, under inert atmosphere, in 
EtOH (6.62 ml). To resulting solution, concentrated hydrochloric acid (1.32 ml) was 
dropwise added in an ice bath. Finally cold NaNO2 10% (3.31 ml) was added and the 
mixture was stirred, at room temperature, overnight. The reaction mixture was 
extracted with AcOEt and the organic phase was dried and evaporated. The crude 
product was purified by chromatography column in silica gel (CH2 Cl2 / CH3 OH 
98:2; 95:5) to afford compound 5 (30 mg, 0.079 mmol) as a white solid with a yield 
of 24%. 
 
1
H  NMR (DMSO-d6)  δ ppm: 
3.80 (s, 2H); 7.10 (double AA’XX’, 2H, JAX= 8.9, JAA’/XX’= 2.6, JHF-o= 9.7); 7.28- 
7.34 (m, 4H); 7.60- 7.64 (m, 2H); 9.42 (bs,1H); 12.19 (bs, 1H) 
 
13
C  NMR  (DMSO-d6)  δ ppm: 
35.08; 114.86 (d, 2C, J= 21.1); 120.08 (q, J= 255.8); 121.50 (2C); 122.64 (2C); 
130.89 (d, 2C, J= 8.0); 133.46 (d, J= 3.0); 136.96; 143.83; 148.98; 153.27; 160.92 
(d, J= 242.0); 170.27  
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A solution  of NH2 NH2 hydrate (0.12 ml, 3.91 mmol) in isopropyl alcohol (32.6 ml) 
was stirred in a flame-dried two-necked flask, under inert atmosphere. Then, 4-fluoro 
phenyl isothiocyanate (500 mg, 3.26 mmol) was added. Once  the addiction was 
completed, stirring was continued for 1h at room temperature. The crude product was 
purified by a filtration with a glass septum. Finally, the white solid obtained 
(compound 39, 474 mg, 2.56 mmol) was dried under reduced pressure. The yield of 
this reaction was 78%. 
 
1 
H  NMR  (DMSO-d6)  δ ppm: 
4.78 (bs, 2H); 7.08 - 7.16 (m, 2H); 7.56 – 7.65 (m, 2H); 9.10 (bs, 1H) 
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To the compound 9 (686.8 mg, 2.56 mmol) in a two-necked round bottomed flask, a 
solution of KOH 1M (7.68 ml, 7.68 mmol) was added. The mixture was refluxed at 
115 °C for 4 h. After cooling at room temperature, it was acidified, in an ice bath,  
with acetic acid. Then compound 39 (474 mg, 2.56 mmol) in EtOH (7.68 ml) was 
added. The resulting solution was stirred and refluxed at 105 °C for 5 h. The reaction 
mixture was extracted with AcOEt . The organic phase was dried and evaporated 
under reduced pressure. The crude product was purified by a column chromatography 
in silica gel (n-Hexane / AcOEt  85:15) to afford compound 15 (498.8 mg, 1.51 
mmol) as an orange solid with a yield of 59%. 
 
1
H  NMR  (CDCl3)  δ ppm: 
3.94 (s, 2H); 7.01 (double AA’XX’, 2H, JAX= 8.8, JAA’/XX’= 2.6, JHF-o= 9.2); 7.15- 
7.23 (m, 4H); 7.29- 7.33 (m, 2H) 
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A solution of compound 15  (498.8 mg, 1.51 mmol) in CH3 OH (1.51 ml) under 
argon was cooled and treated with a solution of CH3 ONa/CH3 OH (0.36 ml, 1.51 
mmol). Then CH3 I (0.12 ml, 1.56 mmol) was added and the resulting mixture was 
stirred at room temperature for 15’. The crude solution was evaporated and was used 
in the next step without any further purification. 
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To a stirred solution of compound 22 (521.5 mg, 1.51 mmol) in isopropyl alcohol 
(5.32 ml) in a flame-dried two-necked round bottomed flask, hydrazine (1.06 ml) was 
added under argon atmosphere. The resulting mixture was refluxed at 105 °C for 3 h. 
After cooling at RT, the crude solution was dried, concentrated and purified with a 
silica gel column (n-Hexane / AcOEt 8:2; 7:3; 6:4) to afford  compound 29 (128.5 
mg, 0.390 mmol) as a white solid. The yield of this reaction was 26%. 
 
1 
H  NMR  (CDCl3)  δ ppm: 
4.06 (s, 2H); 4.66 (bs, 2H); 6.96 (double AA’XX’, 2H, JAX= 8.8, JAA’/XX’= 2.6, JHF-o= 
9.7); 7.06 (double AA’XX’, 2H, JAX= 8.2, JAA’/XX’= 2.7, JHF-o= 8.7);  7.36 (double 
AA’XX’, 2H, JAX= 8.7, JAA’/XX’= 2.6, JHF-m= 5.5);  7.60 ( double AA’XX’, 2H, JAX= 
8.9, JAA’/XX’= 2.9, JHF-m= 4.7) 
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Compound 29 (128 mg, 0.390 mmol) was dissolved, under inert atmosphere, in EtOH 
(6.40 ml). To resulting solution, concentrated hydrochloric acid (1.28 ml) was 
dropwise added in an ice bath. Finally cold NaNO2 10% (3.20 ml) was added and the 
mixture was stirred, at room temperature, overnight. The reaction mixture was 
extracted with AcOEt and the organic phase was dried and evaporated. The crude 
product was purified by chromatography column in silica gel (CHCl3 / CH3OH 95:5; 
95:5) to afford compound 6 (65.5 mg, 0.208 mmol) as a white solid with a yield of 
53%. 
 
1 
H  NMR (DMSO-d6)  δ  ppm: 
3.80 (s, 2H); 7.10 (double AA’XX’, 2H, JAX= 8.9, JAA’/XX’= 2.6, JHF-o= 9.6); 7.17 
(double AA’XX’, 2H, JAX= 8.9, JAA’/XX’= 2.9, JHF-o= 10.4); 7.29 (double AA’XX’, 
2H, JAX= 8.8, JAA’/XX’= 2.6, JHF-m= 5.6); 7.49 (double AA’XX’, 2H, JAX= 9.1, JAA’/XX’= 
2.9, JHF-m= 4.9); 9.26 (bs, 1H); 12.11 (bs, 1H) 
 
13
C  NMR  (DMSO-d6)  δ  ppm: 
35.05; 114.82 (d, 2C, J= 21.3); 115.27 (d, 2C, J= 22.1); 123.62 (d, 2C, J= 8.1); 
130.84 (d, 2C, J= 8.1); 133.55 (d, J= 3.2); 133.82 (d, J=2.6); 148.68; 153.56; 157.31 
; 160.89 (d, J= 241.9); 161.00 (d, J= 256.2)  
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Under argon atmosphere, CS2 (0.66 ml, 10.92 mmol) and Et3N (0.51 ml, 3.64 mmol) 
were added to a solution of 3, 4-(methylenedioxy)aniline (500 mg, 3.64 mmol) in 
EtOH (7.28 ml) at room temperature and the mixture was stirred for 30’ in a flame-
dried two-necked round bottomed flask. After being cooled using an ice bath, the 
reaction solution was treated with a solution of Boc2O ( 794.2 mg, 10.92 mmol) in 
EtOH (3.64 ml) and DMAP. Once the addiction was completed, the stirring was 
continued for 5’ in an ice bath and then for 20’ at room temperature. The crude 
solution was evaporated and purified with a chromatography column in silica gel ( n-
Hexane / AcOEt 98:2) to afford compound 35 (480.9 mg, 2.68 mmol) as a white 
solid. The yield of reaction was 74%. 
 
1
H  NMR  (DMSO-d6)  δ  ppm: 
6.10 (s, 2H); 6.96 (d, 2H, J= 1.2); 7.12 (t, 1H, J= 1.2) 
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A solution  of NH2 NH2 hydrate (0.08 ml, 2.74 mmol) in isopropyl alcohol (22.8 ml) 
was stirred in a flame-dried two-necked flask, under inert atmosphere. Then, 
compound 35 (480.9 mg, 2.68 mmol) was added. Once  the addiction was completed, 
stirring was continued for 1h at room temperature. The crude product was purified by 
a filtration with a glass septum. Finally, the white solid obtained (compound 40, 
509.6 mg, 2.41 mmol) was dried under reduced pressure. The yield of this reaction 
was 90%. 
 
1
H  NMR (DMSO-d6)  δ ppm: 
4.74 (bs, 2H); 6.00 (s, 2H); 6.83 (d, 1H, J= 8.0); 6.90 - 6.92 (m, 1H), 7.29 (bs, 1H); 
9.04 (bs, 1H); 9.49 (bs, 1H)  
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To the compound 9 (456.1 mg, 1.70 mmol) in a two-necked round bottomed flask, a 
solution of KOH 1M (5.11 ml, 5.11 mmol) was added. The mixture was refluxed at 
115 °C for 4 h. After cooling at room temperature, it was acidified, in an ice bath,  
with acetic acid. Then compound 40 (360 mg, 1.70 mmol) in EtOH (5.11 ml) was 
added. The resulting solution was stirred and refluxed at 105°C for 5h. The reaction 
mixture was extracted with AcOEt . The organic phase was dried and evaporated 
under reduced pressure. The crude product was purified by a column chromatography 
in silica gel (n-Hexane / AcOEt  85:15) to afford compound 16 (376.5 mg, 1.05 
mmol) as a yellow solid with a yield of 62%. 
 
1 
H  NMR (CDCl3)  δ ppm: 
3.93 (s, 2H); 6.05 (d, 2H, J= 5.5); 6.63 - 6.66 ( m, 2H); 6.91 (d, 1H, J= 7.6); 7.01 
(double AA’XX’, 2H, JAX= 8.7, JAA’/XX’= 2.5; JHF-o= 9.5); 7.29- 7.33 (m, 2H) 
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A solution of compound 16  (658.9 mg, 1.84 mmol) in CH3 OH ( 1.84 ml) under 
argon was cooled and treated with a solution of CH3ONa/CH3OH (0.44 ml, 1.84 
mmol). Then CH3 I (0.12 ml. 1.90 mmol) was added and the resulting mixture was 
stirred at room temperature for 15’. The crude solution was evaporated and was used 
in the next step without any further purification. 
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To a stirred solution of compound 23 (683.4 mg, 1.84 mmol) in isopropyl alcohol 
(6.48 ml) in a flame-dried two-necked round bottomed flask, hydrazine (1.30 ml) was 
added under argon atmosphere. The resulting mixture was refluxed at 105 °C for 3 h. 
After cooling at RT, the crude solution was dried, concentrated and purified with a 
silica gel column (n-Hexane / AcOEt 8:2) to afford  compound 30 (151.2 mg, 0.43 
mmol) as a white solid. The yield of this reaction was 23%. 
 
1
H  NMR  (CDCl3)  δ  ppm: 
4.05 (s, 2H); 5.97 (s, 2H);  6.77 (d, 1H, J= 8.3);  6.91 (dd, 1H, J= 8.3, 2.2); 6.96 
(double AA’XX’, 2H, JAX= 8.7, JAA’/XX’= 2.5, JHF-o= 9.5); 7.30 (d, 1H, J= 2.1); 7.35 
(double AA’XX’, 2H, JAX= 8.7, JAA’/XX’= 2.6, JHF-m= 5.5) 
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Compound 30 (151.2 mg, 0.43 mmol) was dissolved, under inert atmosphere, in 
EtOH (7.56 ml). To resulting solution, concentrated hydrochloric acid (1.51 ml) was 
dropwise added in an ice bath. Finally cold NaNO2 10% (3.78 ml) was added and the 
mixture was stirred, at room temperature, overnight. The reaction mixture was 
extracted with AcOEt and the organic phase was dried and evaporated. The crude 
product was purified by chromatography column in silica gel (CH Cl3 / CH3 OH 95:5; 
95:5) to afford compound 7 (11.2 mg, 0.33 mmol) as a yellow-white solid with a 
yield of  8%. 
 
1
H  NMR  (DMSO-d6)  δ  ppm: 
3.79 (s, 2H); 6.01 (s, 2H);  6.80 (dd, 1H, J= 8.3, 2.1); 6.87 (d, 1H, J= 8.3); 7.07 - 7.14 
(m, 3H); 7.29 (double AA’XX’, 2H, JAX= 8.7,JAA’/XX’=2.4, JHF-m= 5.6) 
 
13
C  NMR  (DMSO-d6)  δ  ppm: 
35.11; 101.20; 104.73; 108.05; 114.91 (d, 2C, J= 21.2); 115.58; 130.94 (d, 2C, J= 8); 
131.24; 133.63 (d, J= 3.4); 143.99; 147.22; 148.53; 153.78; 160.96 (d, J= 241.9); 
162.46 
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